Recombinant KIR2DL2 (Lirilumab Biosimilar) antibody

Catalog No. ABIN7597791

Product Details anti-KIR2DL2 (Lirilumab Biosimilar) Antibody

Target: KIR2DL2 (Lirilumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Human

Expression System: Mammalian cells

Clonality: Monoclonal

Conjugate: This KIR2DL2 (Lirilumab Biosimilar) antibody is un-conjugated

Application: Please inquire

Purpose: Research Grade Lirilumab Biosimilar Antibody

Specificity: CD158 antigen-like family member A, KIR2DL1, Killer cell immunoglobulin-like receptor 2DL1, Natural killer-associated transcript 1, NKAT-1, MHC class I NK cell receptor, CD158A, p58 natural killer cell receptor clones CL-42/47.11, CD158a, p58.1 MHC class-I-specific NK receptor, NKAT1, p58 NK receptor CL-42/47.11, p58 NK receptor CL-43, NKAT-6, NKAT6, MHC class I NK cell receptor, CD158 antigen-like family member B1, CD158b1, p58 natural killer cell receptor clone CL-43, Natural killer-associated transcript 6, CD158B1, KIR2DL2, Killer cell immunoglobulin-like receptor 2DL2, NKAT2b, KIR2DL3, p58 natural killer cell receptor clone CL-6, p58.2 MHC class-I-specific NK receptor, CD158 antigen-like family member B2, MHC class I NK cell receptor, KIR-023GB, Killer inhibitory receptor cl 2-3, p58 NK receptor CL-6, CD158b2, Killer cell immunoglobulin-like receptor 2DL3, Natural killer-associated transcript 2, CD158B2, KIRCL23, NKAT-2, NKAT2a, NKAT2

Purification: Protein A or G purified from cell culture supernatant.

Purity: >95 % by SDS-PAGE.

Grade: Research Grade

Isotype: IgG4 kappa

Application Details

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: 0.01M PBS, pH 7.4.

Storage: 4 °C,-20 °C,-80 °C

Storage Comment: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.

Expiry Date: 12 months

Target Details for KIR2DL2 (Lirilumab Biosimilar)

Target: KIR2DL2 (Lirilumab Biosimilar)

Alternative Name: Lirilumab Biosimilar (KIR2DL2 (Lirilumab Biosimilar) Products)

Target Type: Biosimilar

Background: CD158 antigen-like family member A, KIR2DL1, Killer cell immunoglobulin-like receptor 2DL1, Natural killer-associated transcript 1, NKAT-1, MHC class I NK cell receptor, CD158A, p58 natural killer cell receptor clones CL-42/47.11, CD158a, p58.1 MHC class-I-specific NK receptor, NKAT1, p58 NK receptor CL-42/47.11, p58 NK receptor CL-43, NKAT-6, NKAT6, MHC class I NK cell receptor, CD158 antigen-like family member B1, CD158b1, p58 natural killer cell receptor clone CL-43, Natural killer-associated transcript 6, CD158B1, KIR2DL2, Killer cell immunoglobulin-like receptor 2DL2, NKAT2b, KIR2DL3, p58 natural killer cell receptor clone CL-6, p58.2 MHC class-I-specific NK receptor, CD158 antigen-like family member B2, MHC class I NK cell receptor, KIR-023GB, Killer inhibitory receptor cl 2-3, p58 NK receptor CL-6, CD158b2, Killer cell immunoglobulin-like receptor 2DL3, Natural killer-associated transcript 2, CD158B2, KIRCL23, NKAT-2, NKAT2a, NKAT2

UniProt: P43626, P43627, P43628

CAS-No: 1000676-41-4